Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2018 1
2020 1
2021 1
2022 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ; KEYNOTE-826 Investigators. Colombo N, et al. N Engl J Med. 2021 Nov 11;385(20):1856-1867. doi: 10.1056/NEJMoa2112435. Epub 2021 Sep 18. N Engl J Med. 2021. PMID: 34534429 Clinical Trial.
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.
Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Fariñas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesta MP; AtTEnd study group. Colombo N, et al. Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2. Lancet Oncol. 2024. PMID: 39102832 Clinical Trial.
Leukemoid reaction with 18F-FDG PET/CT in ovarian carcinoma.
Reguera Berenguer L, Pérez Pascual R, García García JF, de Santiago García J, Márquez Vázquez R, Alonso Farto JC. Reguera Berenguer L, et al. Among authors: marquez vazquez r. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022 Mar-Apr;41(2):115-117. doi: 10.1016/j.remnie.2022.01.001. Epub 2022 Feb 20. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022. PMID: 35193815 No abstract available.
[Consensus for hospital discharge reports in medical specialities].
Conthe Gutiérrez P, García Alegría J, Pujol Farriols R, Alfageme Michavilla I, Artola Menéndez S, Barba Martín R, Cañones Garzón PJ, Casado Pérez P, de Alvaro Moreno F, Escosa Royo L, Jovell Fernández A, León Gil C, Lisbona Gil A, Márquez Vázquez R, Pastor Rodríguez-Moñino A, Pérez Martínez DA. Conthe Gutiérrez P, et al. Among authors: marquez vazquez r. Med Clin (Barc). 2010 Apr 17;134(11):505-10. doi: 10.1016/j.medcli.2009.12.002. Epub 2010 Feb 26. Med Clin (Barc). 2010. PMID: 20189203 Spanish. No abstract available.
Leukemoid reaction with 18F -FDG PET/CT in ovarian carcinoma.
Reguera Berenguer L, Pérez Pascual R, García García JF, de Santiago García J, Márquez Vázquez R, Alonso Farto JC. Reguera Berenguer L, et al. Among authors: marquez vazquez r. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2020 Oct 15:S2253-654X(20)30168-2. doi: 10.1016/j.remn.2020.08.012. Online ahead of print. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2020. PMID: 33071175 English, Spanish. No abstract available.